Tiziana Life Sciences doses first patients in Phase 2a intranasal foralumab ALS trial

Bitget2026/09/28 11:00

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Tiziana Life Sciences dosed the first three participants in a Phase 2a trial of intranasal foralumab in ALS.
No results have been presented; the study is designed to generate safety data and biomarker signals over a 24-week treatment plan.
Primary readout targets tolerability, with secondary measures aimed at showing immune modulation with potential relevance to neuroinflammation.
Trial enrollment targets 44 early-stage ALS patients, using a 3:1 randomization between active drug and placebo.
Program funding includes support from the ALS Association, positioning the asset for a clearer go/no-go decision on further development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609280700OMX_____CNEWS_EN_GNW9834860_en) on September 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Tiziana Life Sciences doses first patients in Phase 2a intranasal foralumab ALS trial

You may also like

Crypto prices